NEUROCRINE BIOSCIENCES INC Operating Leases, Rent Expense
NEUROCRINE BIOSCIENCES INC (NBIX) reported Operating Leases, Rent Expense of $6.90 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2019-02-08
- NEUROCRINE BIOSCIENCES INC operating leases, rent expense for fiscal 2018 was $6.90M, a 16.95% increase from fiscal 2017.
- NEUROCRINE BIOSCIENCES INC operating leases, rent expense for fiscal 2017 was $5.90M, a 1.67% decline from fiscal 2016.
- NEUROCRINE BIOSCIENCES INC operating leases, rent expense for fiscal 2016 was $6.00M, a 0.00% change from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC operating leases, rent expense for fiscal 2015 was $6.00M, a 0.00% change from fiscal 2014.
| Period end | Operating Leases, Rent Expense 12 month | Operating Leases, Rent Expense 12 month as first filed |
|---|---|---|
| 2018-12-31 | $6.90M 10-K · filed 2019-02-08 | |
| 2017-12-31 | $5.90M 10-K · filed 2019-02-08 | |
| 2016-12-31 | $6.00M 10-K · filed 2019-02-08 | |
| 2015-12-31 | $6.00M 10-K · filed 2018-02-13 | $5.90M 10-K · filed 2016-02-11 |
| 2014-12-31 | $6.00M 10-K · filed 2017-02-14 | $5.90M 10-K · filed 2015-02-09 |
| 2013-12-31 | $5.90M 10-K · filed 2016-02-11 | |
| 2012-12-31 | $5.90M 10-K · filed 2015-02-09 | |
| 2011-12-31 | $6.20M 10-K · filed 2014-02-11 | |
| 2010-12-31 | $6.40M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |